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TB infection remains a leading cause of morbidity and mortality among patients with HIV infection, 
while HIV is the strongest risk factor for development of active TB. Integration of HIV and TB 
treatment is key to reducing mortality in co-infected patients; but many obstacles stand in the way of 
effective scale-up of this approach to HIV-TB treatment. The challenges associated with HIV-TB 
integration extend from clinical complexities in individual patient management, to impediments in 
health service organization and prioritization to address this urgent public health priority, especially in 
sub-Saharan Africa where TB-HIV co-infection rates reach 80%. 
  
The purpose of this study was to assess and identify strategies to overcome the challenges in immune 
reconstitution and drug safety/tolerability when integrating HIV and TB care in a cost-effective manner 
to reduce co-infection mortality. 
 
Clinical and operational service data from the Starting Antiretroviral therapy at three Points in 
Tuberculosis Treatment (SAPiT – CAPRISA 003) study, a 3-arm, randomized control trial in 642 newly 
diagnosed sputum smear-positive TB-HIV co-infected adult patients with screening CD4+ cell count < 
500 cells/mm3, were analysed. In addition, the incidence rate of unmasked clinical TB following ART 
initiation was assessed through a retrospective chart review conducted in HIV infected patients enrolled 
at the rural CAPRISA AIDS Treatment Programme.   
  
Overall, mortality was 56% lower (RR=0.44; 95% CI: 0.25 to 0.79; P = 0.003) in patients initiated on 
ART during TB treatment compared to ART deferral to after TB treatment completion. However, the 
risk of immune reconstitution inflammatory syndrome (IRIS) was higher (incidence rate ratio (IRR), 
2.6 (95% CI, 1.5 to 4.8); P < 0.001, in patients initiating ART within the first 2 months compared to 
later ART initiation during TB treatment. In the most severely immuno-compromised patients (CD4 
counts <50 cells/mm3) early ART integration was associated with an almost five-fold increased risk of 
IRIS (IRR 4.7 (95% CI, 1.5 to 19.6); P = 0.004. Patients initiating ART in the first 2 months of TB 
therapy had higher hospitalization rates (42% vs. 14%; P = 0.007) and longer time to resolution (70.5 
vs. 29.0 days; P = 0.001) than patients in the other two groups. When assessing available evidence, 
these results indicate that ART initiation in patients with CD4 cell counts >50 cells/mm3 would be most 
appropriate after completion of intensive phase of TB therapy, a strategy that was found to cost $1840 
per patient treated. Among HIV infected patients initially screening negative for TB there was a four-
fold higher incidence rate of unmasking TB in the first 3 months after ART initiation, compared to the 
subsequent 21 months post-ART initiation. 
 
xvi 
The new information generated by this study provides important evidence for policy and clinical 
management of patients with HIV and TB co-infection. Firstly, careful clinical vigilance for ‘unmasked’ 
TB is required in patients initiating ART. Secondly, the survival benefit of AIDS therapy in TB patients 
can be maximized by initiating ART as soon as possible after TB therapy has been started in patients 
with advanced immunosuppression, i.e., those with CD4+ counts <50 cells/mm3.  However, patients 
with higher CD4+ cell counts should delay ART initiation to at least 8 weeks after the start of TB 
therapy to minimize the incidence and duration of immune reconstitution disease and consequent 
hospitalization. Thirdly, this approach, which is at variance with current World Health Organization 
policy and guidelines, is cost-effective and readily implementable within the clinical setting. Finally, 
addressing the operational challenges to HIV-TB treatment integration can improve patient outcomes 








1.1 Summary of the HIV-TB treatment context 
Tuberculosis (TB) infection contributes extensively to morbidity and remains a leading infectious cause 
of death among patients with HIV, while HIV remains the strongest risk factor for development of 
active TB. In sub-Saharan Africa (SSA) TB-HIV co-infection rates are as high as 80%, with South 
Africa holding a disproportionate burden of these two diseases with approximately 12.2% of the 
population infected with HIV in 2012 and 450000 new TB cases notified in 2013 alone. In 2004, the 
WHO proposed an interim policy for collaborative TB/HIV activities. Yet, in 2010, only 34% of TB 
patients underwent HIV testing, and only 46% of HIV-positive TB patients received antiretroviral 
therapy (ART). Finding the optimal time to initiate ART in TB HIV co-infected patients remained an 
urgent public health priority. The timing of ART initiation in TB patients presents a clinical challenge 
of competing risks and benefits. On one hand, deferred ART to after the start of TB therapy is associated 
with increase mortality and AIDS disease progression, while early initiation of ART during TB therapy 
raises concerns over increase risk of immune reconstitution inflammatory syndrome, non-adherence 
from the high pill burden, and overlapping side effects from co-administration of three antiretroviral 
drugs with the standard four drug anti-tuberculosis therapy. In addition, the translation from research to 
implementation of TB HIV co-treatment as part of national health guidelines, has uncertain cost 
implication. Observational and cohort studies prior to 2010 offered guidance but the lack of randomized 
control clinical trials investigating optimal timing of ART initiation in TB patients left many important 
yet unanswered questions. 
 
1.2 Aims and Objectives 
 
The overarching aim of the study was to assess the impact of ART initiation in TB-HIV co-infected 
patients with respect to mortality; unmasking TB; TB associated immune reconstitution inflammatory 
syndrome, drug tolerability and additive toxicity, and costs and cost effectiveness of co-treatment. 
Specific Objectives 
1. To quantify the burden of HIV associated TB among patients initiating antiretroviral therapy 
in rural KwaZulu-Natal 
2. To assess IRIS incidence, severity, and outcomes in patients with HIV-related tuberculosis 
receiving integrated compared to sequential TB and HIV treatment. 
3. To assess the costs and cost effectiveness of starting ART at various time points during TB 




1. To compare morbidity and mortality in patients receiving integrated compared to sequential TB 
and HIV care.  
2. Review and critically appraise the literature to determine the optimal timing of ART initiation 
in TB HIV co-infected patients. 
3. To assess drug tolerability and toxicity when combining ART with anti-TB drugs in patients 
with HIV related tuberculosis receiving integrated compared to sequential TB and HIV care. 
 
1.3 Literature Review 
 
1.3.1 The Epidemiologic burden of TB-HIV co-infection 
Tuberculosis (TB) infection contributes extensively to morbidity and remains a leading infectious cause 
of death among patients with HIV (1-5). In 2013, global estimates of individuals with HIV infection 
was 35.2 million (6), and TB infection 2.2 billion, with 9.4 million new cases of TB disease (7). HIV 
remains the strongest risk factor for TB among those with new or latent Mycobacterium tuberculosis 
(MTB) infection (8-11), and has also been strongly associated with an increased risk of TB associated 
death. The risk of TB disease is highest soon after HIV sero-conversion, doubles within the first year 
of HIV acquisition (5, 12, 13), and becomes more pronounced with advancing immunosuppression (14, 
15).  The risk of TB in individuals with HIV infection is 20-37 (16) times higher than in those without 
HIV infection, and in some settings in sub-Saharan Africa (SSA), the prevalence of  HIV co-infection 
in TB patients is as high as 907 per 100 000 population (Table 1). Approximately 75% of all HIV-
associated TB occurs in Africa with countries in sub-Saharan Africa reporting HIV co-infection rates 
of more than 50% of all TB cases notified (Figure 1) (7).  
 
Table 1: HIV Prevalence in new TB cases: sub-Saharan Africa region, 2013 (7) 
Rank Country Rate per 100,000 
1 Swaziland 907 
2 Zimbabwe 433 
3 Lesotho 424 
4 South Africa 857 
 
The global burden of TB- HIV-co-infection peaked at 1.4 million cases in 2005, with approximately 
480 000 TB deaths among co-infected patients accounting for about 25% of all deaths in HIV infected 
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patients (Figure 1) (7, 11, 17, 18). In addition, data showing 1.1 million HIV-TB co-infected cases 
reported in 2014, indicates that the burden of HIV-associated TB remains ongoing (7). 
 
 
Figure 1: Global HIV Prevalence in new TB cases, 2013 (~13% of 9 million new TB cases were in 
people with HIV 360 000 deaths were from HIV-associated TB) (7) 
A total of 1.5 million people died from TB disease in 2013 (7). Of concern, 360 000 of these TB patients 
who died were HIV-positive (Figure 2) (7).  South Africa holds a disproportionate burden of these two 
diseases with approximately 12.2% of the population (6.4 million persons) infected with HIV in 2012 
(19), and 450 (410–520) thousand new TB cases notified in 2013 alone (7). The province of KwaZulu-
Natal, South Africa, one of the global epicentres of TB HIV co-infection, has a population of 
approximately 1.2 million HIV-infected individuals, a TB co-infection rate of 70% (20) and a 
background TB notification rate of 1094 cases per 100,000 population (7, 21, 22).  
 
Identifying effective mechanisms of reducing the nearly 0.5 million HIV associated TB deaths that 




Figure 2: Global and South African TB and HIV epidemics in  2012 (6, 7) 
1.3.2 The epidemiologic Interaction between TB and HIV 
Tuberculosis, first introduced to South Africa in the 17th century by European immigrants, became 
established among miners and their families in rural communities in the 19th century (23). Although TB 
incidence rates increased to approximately 350/100 000 population in the 1960s, reports show a decline 
during the 1970s (24). The central tenet of tuberculosis control, the WHO DOTS strategy, was based 
on the principles of prompt detection and effective treatment of infectious patients with the goal of 
interruption of TB transmission and reduction in TB prevalence (25, 26). The rising HIV prevalence in 
sub-Saharan Africa (Figure 3) (27), contributes to increased TB susceptibility at a population level. The 
increasing burden of TB fostered by the HIV epidemic has generated several challenges in DOTS as 
the mainstay of the TB control strategy. HIV mediates increased susceptibility to active tuberculosis 
through reactivation of latent TB infection or progression of newly acquired TB infection to disease 
(28, 29). The escalating numbers of TB cases resulting from the maturing HIV epidemic plunged South 
Africa into having one of the worst TB crisis in the world. TB notification rate showed an almost 4-fold 
increase from 163/100,000 in 1986, to 628/100,000 in 2006 (30).  
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Figure 3: Escalation in TB notification rates in sub-Saharan Africa secondary to rising HIV 
prevalence. (27) Reproduced with permission from Elsevier (License no. 3743100042132). 
 
The striking difference in TB susceptibility and TB outcomes among HIV infected and uninfected 
patients was demonstrated in South African gold miners, where TB notification rates among HIV-
negative miners remained stable between 1990 and 1999 , compared to the 4-fold  increase in TB 
notification rates among HIV-positive miners (31). Furthermore, TB mortality rates in the general 
population increased 2.8-fold from 78/100,000 in 1990 to 218/100,000 in 2006 (20).  
 
The impact of HIV on the increasing burden of tuberculosis at a population level was described  in rural 
KZN using census derived estimates that showed an increase in TB incidence from 154/100 000 in 1991 
to 413/100 000 in 1995 (32). This increase occurred while the prevalence of HIV infection in women 
attending antenatal clinics in KwaZulu-Natal increased from 1.61% in 1990 to 18.23% in 1995. 
Furthermore, the proportion of tuberculosis cases attributable to HIV infection was estimated to be at 
least 44% in 1995 (32).  
 
1.3.3 Rationale for TB and HIV treatment integration 
The epidemiology of the TB and HIV epidemics overlap substantially and significant benefits exist to 
both programs, to patients and their communities if both TB and HIV are simultaneously addressed via 
an integrated approach. The development of simple and sustainable strategies for HIV care delivery to 
large numbers of patients in resource poor settings remains a key priority especially as increasing 
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evidence became available on the substantial morbidity and mortality benefit through use of ART 
therapy (33).  Various models of HIV care provision were suggested, and among these was a proposed 
strategy to integrate HIV care into existing TB programs (34-36).  
 
As TB remains the commonest presentation of AIDS in most resource limited settings, HIV screening 
in TB programs provides a cost-effective method of identifying patients likely to benefit from 
antiretroviral therapy and an efficient mechanism for rapidly scaling up ART initiation given the large 
co-infection disease burden (11, 37). In 2010, despite evidence in support of this approach, only 34% 
of TB patients underwent HIV testing, and only 46% of HIV-positive TB patients received antiretroviral 
therapy (18).  
 
Existing TB services in many developing countries offer the opportunity of utilising existing established 
infrastructure for expansion to include HIV services: including laboratory and radiological support 
services, systems for drug procurement, and systems to monitor treatment adherence and toxicity.  The 
multitude of potential benefits to integration include an increase in HIV and TB case detection through 
efficient targeted screening in HIV and TB populations, the use of an established TB infrastructure to 
deliver AIDS care, and an opportunity to reduce the TB case fatality rate in HIV infected patients (38). 
While it was proposed that this strategy would enable initiation of ART for newly identified HIV 
infected patients during TB treatment and facilitate management of those who develop TB during 
treatment for HIV, evidence to support improved outcomes and guidance for successful implementation 
of this strategy was lacking. Furthermore, the timing of ART in TB patients presents a clinical challenge 
of competing clinical risks and benefits (Figure 4) (39). On one hand, deferred ART to after the start of 
TB therapy is associated with increase mortality and AIDS disease progression, while early initiation 
of ART during TB therapy raises concerns over increase risk of non-adherence to TB therapy and ART 
from the high pill burden associated with dual therapy, immune reconstitution inflammatory syndrome, 
and overlapping side effects from co-administration of three antiretroviral drugs with the standard four 




Figure 4: Risks and benefits of early versus later antiretroviral therapy initiation in tuberculosis 
patients (39) 
 
1.4 Impact of TB HIV treatment integration on mortality 
1.4.1 Early evidence describing the impact of ART on mortality in TB-HIV co-infected patients 
Early published data showed higher case fatality rates in HIV associated TB patients despite effective 
TB treatment (40), and extremely high TB associated mortality in HIV infected patients enrolling into 
care programmes (41). Subsequently, evidence emerged showing that ART provision could 
significantly impact TB case fatality in co-infected patients through demonstration that ART use among 
TB patients contributed to substantial decreases in morbidity and mortality (3, 42).  
 
Data published in 2001 from African cohorts demonstrated TB case fatality rates of 16% to 35% among 
HIV infected patients not receiving ART compared to 4% to 9% among HIV uninfected patients. 
Subsequent to publication of these findings, data from several cohort and observational studies (n=11) 
provided information on the impact of ART on survival of patients with HIV-associated TB (Table 2), 
by demonstrating that concurrent ART reduced mortality risk by 64% to 95% in patients receiving 
treatment for HIV-associated TB (41-49). 
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Table 2: Data from Cohort and observational studies evaluating the Impact of ART on mortality in HIV infected TB patients: 2004-2009 
Main Author Journal and 
Year of 
Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on Mortality 
Gandhi, N.R J AIDS (2009) Successful integration of 
TB-HIV treatment in rural 
SA 
Address barriers to effective care for 
TB/HIV infected patients using TB-
HIV integration strategy (concomitant 




South Africa 119 TB-HIV Therapy may be safely and 
effectively integrated to improve TB 
& HIV outcomes and mortality in 
TB/HIV infected patients in resource 
limited settings. 
Varma, J.K BMC Infectious 
Dis. (2009) 
HIV care and Treatment 
factors associated with 
improved survival during 
TB Treatment in Thailand 
• Identify and quantify the relative 
benefit of biomed interventions 
assoc. with survival during TB 
TREATMENT 
• to evaluate the optimum time to 
initiate ART,  
• evaluate the AEs and survival 





Thailand 667 Patients who took ART had 1/5 the 
risk of dying than those who did not 
take ART, risk of dying was further 
reduced with early ART initiation and 
concomitant use of fluconazole. 
Velasco, M J AIDS (2009) Effect of simultaneous use 
of HAART on survival of 
HIV-TB patients 
• Assess the effect of HAART on the 
survival of patients with TB 
COMESEM 
Cohort Study 
Spain 6934 Simultaneous HAART And TB 
Treatment in HIV-TB patients is 
associated with improved survival. 




Early versus Delayed fixed 
dose combination 
Abacavir/lamivudine/zido
vudine in patients with 
HIV-TB  
• To assess efficacy and safety of 
ABC/3TC/ZDV in co-infected 
patients. 
• To compare clinical outcomes 
relative to initiation of anti-TB 
therapy between patients 




Tanzania 70 Early ART can be well tolerated by 
HIV/TB co-infected subjects with low 
risk IRIS, there may be more AE’s 
with early ART which warrants 
regimen switches. 
Early ART lead to virologic 
suppression and increased CD4. 
Haar, C.H INT J 
TUBERC 
LUNG DIS  
(2007) 
HIV- related mortality 
among TB patients in 
Netherlands 1993-2001 
To describe the prevalence and 
predictive factors of HIV infection 















Mortality rates among HIV infected 
patients decreased over time, 
probably related to the more 
widespread introduction of HAART 
Akksilp, S Emerging 
Infectious 
Diseases (2007) 
ART during TB treatment 
& marked reduction in 
death rate 
Estimate the benefit of ART in 
reducing mortality during TB 
treatment in HIV-TB infected patients 







Thailand 329 Deaths of patients with TB-HIV 
remain high despite increased access 
to ART, few HIV-TB patients receive 
ART 
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Main Author Journal and 
Year of 
Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on Mortality 




Does ART reduce case 
fatality among HIV + 
patients with TB in 
Malawi 
• To report on case fatality among 
HIV-TB infected patients while on 
TB Treatment 
• Identify whether ART initiated in 





Malawi 983 ART provided in the continuation 
phase does not have significant 
impact on reducing case fatality  
Nahid, P AM J Resp Crit 
Care Med 
(2007) 
Treatment outcomes of 
HIV-TB patients 
To evaluate treatment outcomes for 
HIV infected patients stratified by 




San Francisco  700 HIV infected patients receiving 6-
month rifamycin based 
course/intermittent therapy had higher 
relapse rate than HIV+ patients who 
received longer therapy or daily 
therapy.  
Dheda, K JID (2004) Outcome of HIV 
associated TB in the era of 
HAART 
Compare characteristics and outcome 
of patients infected with TB-HIV 
treated before HAART era vs. during 
HAART era 
Chart review London 96 HAART substantially reduces new 
AIDS events and death in co-infected 
patients.  
Hung, C AIDS (2003) Improved outcomes of 
HIV-1 infected adults with 
TB in the era of HAART 
Compare the survival and treatment 
responses to ART between HIV-1 and 





Taiwan 125 No significant difference between 
groups 
Dean, G.L AIDS (2002) Treatment of TB in HIV 
infected persons in the era 
of HAART 
Assess risk and benefits of 
administering HAART during 
treatment of TB in HIV infected 
patients 
Retrospective 
Case review  
London 188 Use of HAART lead to significant 
reductions in viral load, ADI, 
mortality in co-infected commonly 




These data collectively contribute analysis on 23 507 patients, of these, half of whom were from 
resource-limited settings. Among these eleven studies, eight studies found significant reductions in 
mortality associated with ART use in tuberculosis treatment, whereas three found no impact of ART on 
mortality (Table 2) (43-45, 47, 49-55). A longitudinal cohort study conducted in South Africa, (42) 
demonstrated extremely high rates of AIDS or death among ART naïve patients in the first 6 months 
after enrolling into HIV treatment programmes. The high death rate was seen among WHO stage 3 
patients, before the development of AIDS defining illnesses (ADI), and a high risk of ADI’s was seen 
in those with CD4 cell counts between 200 and 350 cells/mm3 (42), highlighting the need for timely 
ART initiation. The key unanswered question in the clinical management of patients with HIV-
associated TB was the optimal time to start ART during TB treatment. The 2005 WHO Expert 
consultation (56) into research priorities in collaborative TB-HIV activities therefore recommended that 
finding the optimal time to initiate ART in TB-HIV co-infected patients was an urgent public health 
priority. On one hand, mortality rates and AIDS disease progression are extremely high among patients 
waiting to start ART in resource-limited settings, however, early initiation of ART in TB HIV increases 
the risk of immune reconstitution inflammatory disease, morbidity from co-administering TB drugs 
with ART, thereby increasing costs of caring for co-infected patients. In addition, issues of tolerability, 
pill burden, and drug interactions between ART and TB therapy had the potential to undermine both 
ART therapy as well as TB outcomes. 
 
1.4.2 Recent evidence describing the impact of ART on mortality in TB-HIV co-infected patients 
Published data from several large trials including cohort and observational studies and randomised 
control trials (RCTs), became available since 2009 and have informed guidelines (Table 3 and Table 4) 
(46, 52, 57-69) on optimal timing of ART in TB patients. The vast majority of these strategy trials show 
that ART co-administered with TB therapy provides an improved survival benefit, hence the 
recommendation by the WHO that ART be provided to all patients together with their TB treatment, 
regardless of CD4 cell count. There was concurrence in the findings of all these studies regarding 
patients with advanced immunosuppression (CD4 cell counts <50 cells/mm3); mortality was reduced 
when ART was started within the first 2 weeks of TB treatment. For patients with less advanced 
immunosuppression (CD4 cell counts >50 cells/mm3), these studies suggested that ART might be 
deferred until completion of the intensive phase of TB treatment without negatively impacting survival.  
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Table 3: Data from Cohort and observational studies evaluating the Impact of ART on mortality in HIV infected TB patients:  2009-2015 
Main Author Journal and 
Year of 
Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on 
Mortality 
Saraceni, V Braz J Infect Dis 
(2014) 
Survival of HIV patients with TB started 
on simultaneous or deferred  HAART in 
the THRio cohort, Rio de Janeiro, Brazil 
To compared survival 
among patients who 
initiated HAART within 
60 days of TB Treatment 
to those who started 
HAART >60 days of TB 
treatment or never 
started   
Observational 
cohort analysis 
Rio de Janeiro 947 HAART initiated 
early after TB 
Treatment in co-
infected patients was 
associated with 89% 
reduction in the risk 
of death compared 
to delayed HAART 
initiation 
Yang , C BMC Infectious 
Diseases (2014) 
The impact of HAART initiation timing 
on HIV-TB Co-infected patients, a 
retrospective cohort study 
To understand the TB 
outcome of HIV-infected 






Taiwan 229 Initiating HAART 
during TB 
Treatment is 
associate with better 
one-year survival, 
although the earlier 
initiation within 60 
days of TB 
Treatment did not 
show statistical 
differences in 
survival than later 
initiation.  
Han, S HIV Med (2014) Prognostic significance of the intervals 
between the initiation of ART and anti-
TB Treatment in HIV-TB co-infected 
patients: Results from the TREAT Asia 
HIV Observational Database  
This study evaluated the 
effect of time intervals 
between the initiation of 
ART and TB Treatment 
on clinical outcomes in 
HIV-TB co-infected 







768 Treatment outcomes 
and overall mortality 
of HIV-TB co-
infected patients 
who started ART 
within 90 days of 
TB Treatment did 
not differ from those 
who started ART 
started later. 
Overall mortality 
was higher among 
patients diagnosed 
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Main Author Journal and 
Year of 
Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on 
Mortality 
with TB while on 
ART. 
Lettow, M Public Health 
Action (2011) 
Timing and uptake of ART during 
Treatment for active TB, in HIV co-
infected adults in Malawi 
To determine at 
programme level if 
earlier initiation of ART 
in co-infected patients 
receiving TB Treatment 
will increase the uptake 





Malawi 2155 Earlier initiation of 
ART in co-infected 
patients receiving 
TB Treatment 
improved the uptake 




initiating ART after 
2 months to as soon 
as possible 
Franke, MF PLoS Medicine 
(2011) 
Effectiveness of Early ART initiation to 
improve survival among HIV infected 
Adults with TB: A retrospective cohort 
study 
To confirm results from 
randomized trials among 
a cohort of HIV-infected 
adults who were 
diagnosed with TB under 
routine programmatic 
conditions, rather than 




Rwanda 308 Early cART reduced 
mortality among 
individuals with low 
CD4 cell counts and 
improved retention 
in care, regardless of 
CD4 cell count.  
Treatment: Treatment 
Py: person years 
CD4 cell count: cluster of differentiation 4 




Table 4: Data from randomized control trials evaluating the Impact of ART on mortality in HIV infected TB patients:  2009-2015 
Main Author Journal and Year 
of Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on Mortality 
Amogne, W PLOS One (2015) Efficacy and Safety of ART 
initiated 1 week after TB Treatment 
in Patients with CD4 cell count 
<200 cells/mm3: TB-HAART 
Study, a Randomized Clinical Trial  
To determine risk of mortality 
if ART initiated 1, 4 and 8 






478 ART 1 week after TB did not 
improve survival. 
2/3 mortality occurred within 
first 2 weeks 
Mfinanga, S.G Lancet (2014) Early vs. delayed initiation of 
HAART for HIV positive adults 
with newly diagnosed pulmonary 
TB (TB-HAART): a prospective, 
international, randomized, placebo-
controlled trial 
This study assessed the effect 
of early vs. delayed initiation 
of ART on TB Treatment 
outcomes for HIV+ people 
with CD4 cell count of at 
least 220 cells/mm3 with 











1675 ART can be delayed until 
after 6 months of TB 
Treatment for HIV+ patients 
who have CD4 cell count 
>220 cells/mm3. 
No significant difference 
between groups. 
Manosuthi, W J AIDS (2012) Time to ART between 4 weeks and 
12 weeks of TB Treatment in HIV-
infected patients: Results from the 
TIME Study 
The determine the optimal 
timing for ART initiation 
aimed at reducing the 
mortality among HIV infected 





Thailand  156 Immediate ART initiation in 
TB-HIV co-infected patients 
did not confer a survival 
advantage when compared to 
initiation of ART at 12 week. 
Predictors of poorer survival 
included low baseline CD4 
cell counts  
Sinha, S BMC Infectious 
Disease (2012) 
Early vs. delayed initiation of ART 
for Indian HIV infected  individuals 
with TB on anti-TB Treatment 
To compare early (2-4 weeks) 
and delayed (8-12 weeks) 
initiation of ART after 




India 150 No significant difference in 
mortality among HIV-TB co-
infected patients initiating 
ART 2-4 weeks after 
commencing ATT (early ART 
group), and those receiving it 
8-12 weeks after starting ATT 
(delayed ART group).  
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Main Author Journal and Year 
of Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on Mortality 
Torok, M.E CID (2011) Timing of Initiation of ART in HIV 
associated TB-meningitis. 
To determine whether 
immediate ART reduced the 
risk of death 
Randomized, double 
blind, placebo-
controlled trial  
Vietnam 253 Immediate ART does not 
improve mortality in patients 
presenting with HIV-
associated TB meningitis  
The overall, mortality among 
patients with TB meningitis 
who were treated with ART 
was similar to patients who 
did receive Treatment during 
TB Treatment.  
Abdool Karim, S NEJM (2011) Integration of ART with TB 
Treatment 
Determine the impact of ART 
timing on clinical outcomes in 




South Africa 642 The incidence rate of AIDS or 
death in the earlier ART 
group compared to the late-
ART group was 6.9 cases per 
100 py versus 7.8 per 100 py, 
respectively. 
Blanc, F NEMJ (2011) Earlier vs. Later start of ART in 
HIV infected Adults with TB 
To determine whether the 
earlier initiation of ART (2 
weeks after the onset of TB 
Treatment)  as compared with 
later initiation (8 weeks after), 
could reduce mortality among 




centre, open label 
superiority trial 
(CAMELIA) 
Cambodia 661 Initiating ART 2 weeks after 
the start of TB Treatment 
significantly improved 
survival among HIV-infected 
adults with CD4+ T-cell 
counts of 200 cells/mm3 or 
lower 
Havlir, D.V NEJM (2011) Timing of ART for HIV-1 Infection 
and TB 
To determine the proportion 
of patients who survived 
without an AIDS-defining 
illness at 48 weeks  
Open label 
randomized study 
Brazil 809 Overall, immediate ART did 
not reduce AIDS-defining 
illness and death compared to 
early ART.  
For persons with CD4 
lymphocytes < 50 cells/mm3, 
immediate ART had 42% less 
AIDS defining illness and 
death compared to early ART. 
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Main Author Journal and Year 
of Publication 
Title of paper Primary Objectives Study Design Country Sample 
Size 
Impact of ART on Mortality 
Abdool Karim, S NEJM (2010) Timing of Initiation of ART during 
TB Therapy 
To determine the optimal time 
to initiate ART in HIV-TB 





South Africa  642 Initiation of ART during TB 
therapy in patients with 
confirmed HIV-TB co-
infection reduced mortality by 
56%. 




Early versus Delayed fixed dose 
combination 
Abacavir/lamivudine/zidovudine in 
patients with HIV-TB in Tanzania 
Assessment of safety and 
efficacy of ABC/3TC/ZDV in 
TB-HIV co-infected patients 
and to compare outcomes, 
including TB-IRIS, between 
patients in the early vs. 
delayed ART, relative to anti-
TB therapy start.   
Randomized pilot 
study 
Tanzania 70 Early ART can be well 
tolerated by HIV/TB co-
infected subjects with low risk 
IRIS, although more regimens 
switches from treatment 
related AE occurs. 
Early ART lead to benefits in 
virological suppression and 
increased CD4 cell count. 
Treatment: Treatment 
Py: person years 
CD4 cell count: cluster of differentiation 4 
HIV-TB: Patients co-infected with HIV and TB 
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These findings have been incorporated into WHO guidelines which has since recommended that TB-
HIV co-infected patients start TB treatment first, followed by ART as soon as possible within the first 
8 weeks of treatment regardless of CD4 cell count.  In those patients with severe immunosuppression 
(CD4 cell count <50 cells/mm3), ART should however be initiated within the first 2 weeks of TB 
treatment start. It is important to note that patients with HIV associated TB meningitis represent an 
important exception to the above recommendations. Data from a randomized trial found no survival 
benefit from early ART in patients with TB meningitis, instead showing poor prognosis, with extremely 
high mortality rates of approximately 60%, due largely to CNS associated TB-IRIS (67). 
  
1.5 The clinical challenges associated with TB-HIV treatment integration 
The timing of ART in TB patients presents a clinical challenge of competing risks and benefits. On one 
hand, deferred ART to after the start of TB therapy is associated with increased in mortality and AIDS 
disease progression, while early initiation of ART during TB therapy is associated with a concern about 
the increase risk of paradoxical immune reconstitution inflammatory syndrome (IRIS), overlapping side 
effects from co-administration of three antiretroviral drugs and the standard four drug anti-tuberculosis 
therapy, and a high pill burden  (70-74). The occurrence of these clinical challenges can complicate that 
management of TB HIV co-infected patients as it is often difficult to differentiate these from adverse 
events due to ART or TB drugs, failure of TB treatment or occurrence of another HIV-related 
complications. 
 
1.5.1 Immune Reconstitution Inflammatory Syndrome (IRIS) 
IRIS will remain an important medical problem as the global scale up of ART initiation continues 
toward a test and treat approach, expanding rapidly in settings where TB is endemic and patients still 
present for ART at very low CD4 cell counts – all known risk factors for IRIS occurrence. ART enables 
immune recovery through suppression of HIV replication, resulting in an increase in circulating CD4 
cell counts, restoration of immune responses to specific pathogens over time, and ensuing clinical 
benefits. Immune restoration may result in paradoxical clinical deterioration from immune-pathological 
reactions in patients on effective treatment and arises from the body’s renewed ability to produce an 
immunologic response that is inflammatory in nature following initiation of ART or tuberculosis 
treatment.  This clinical scenario is termed “IRIS,” or “immune restoration disease.” Consensus case 
definitions of paradoxical TB IRIS have been published (72), and as there are currently no laboratory 
test to confirm the presence of IRIS, paradoxical IRIS remains a clinical diagnosis only.  While IRIS 
occurrence has been associated with a wide range of infectious agents, and autoimmune phenomena, 
the commonest association has been with mycobacterial infections, especially Mycobacterium 
tuberculosis infection (75). Published evidence from observational and retrospective studies show that 
TB-associated IRIS occurs in approximately 11% to 71.4% of TB HIV co-infected patients that initiate 
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ART (Table 5) (76-81). Reports of high rates of IRIS irrespective of background rates of TB, has been 
a key reason for clinicians deferring ART initiation patients currently receiving TB treatment. 
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Table 5: Impact of ART initiation in TB-HIV co-infected patients on Incidence of paradoxical TB-IRIS: Summary of published studies from cohorts 





Journal  Title of paper Primary Objectives Study Design Country Sample 
Size 











Narita et al 
(1998) 







in Patients with AIDS 
To determine the incidence 
of paradoxical responses in TB-
HIV co-infected patients treated 
with anti-tuberculous therapy and 
subsequently with combination 











Syndrome in HIV/TB 
co-infected patients 
after initiation of 
generic ART in India 
To determine the incidence of 
immune reconstitution in 




India 144 144 11 7.6 
 
 
Breen et al 
(2004) 
Thorax Paradoxical reactions 
during tuberculosis 
treatment in patients 
with and without HIV 
co-infection 
To estimate the frequency and 
nature of paradoxical reactions in 







100 28 8 28.6 
Shelburne et al 
(2005) 
AIDS Incidence and risk 






To determine incidence, risk 
factors, and IRIS outcomes in 
HIV-infected patients, co-
infected with one of three 
common opportunistic 




USA 259 86 26 30.2 





Survival Rate and Risk 




with and without 
antiretroviral therapy 
•To determine possible risk 
factors that related to death 
among patients  
• to determine the appropriate 




Thailand 167 167 21 12.6 
Burman  et al 
(2006) 





Weekly Treatment of 










Journal  Title of paper Primary Objectives Study Design Country Sample 
Size 














kul et al (2007) 
Southeast 




Infected patients on 
ART with TB 
•To determine the clinical 
outcomes of TB in HIV-infected 
patients on ART. 
 
•To investigate the incidence and 
manifestations of adverse events 
and IRIS in association with 
ART initiation.  
Retrospective 
chart review 
Thailand 101 101 15 14.9 





incidence, risk factors 
and impact in an ART 
service in South Africa 
To determine the burden and 
impact of immune reconstitution 
disease associated with TB 






160 160 19 12 
Manosuthi et al 
(2009) 
AIDS Clinical case definition 






•To assess performance of the 
INSHI-2008 definition in a 
clinical trial 
 
•To study the clinical 
manifestations and predictive 
factors for 
paradoxical TB-IRIS among 
patients co-infected with HIV 
and TB  
Prospective 
cohort study 
Thailand 126 126 23 17.5 












Syndrome in HIV and 
TB co-infected persons 
in Thailand 
•To determine specific T helper 1 
cytokine markers to predict and 
diagnose TB-IRIS in HIV and 
TB co-infected adults after 
Initiating ART in Thailand 
•to describe the incidence and 





Thailand 126 126 22 17.5 
Sharma et al 
(2010) 
Indian J Med 
Res 




To describe the frequency and 
risk factors of TB-associated 









Journal  Title of paper Primary Objectives Study Design Country Sample 
Size 
















JIAPAC Evaluation of 
Paradoxical TB-
Associated IRIS With 





To evaluate paradoxical 
tuberculosis (TB)-associated 
IRIS in a large cohort from a TB 
endemic setting with the use of 





313 313 35 11.2 











Syndrome in North 
Indian Population of 
HIV/AIDS Patients 
Receiving HAART 
•To determine the incidence of 
IRIS in patients with HIV-
associated TB  





India 224 123 5 4.1 
Letang et al 
(2011) 
PLOS One Incidence and 
Predictors of Immune 
Reconstitution 
Inflammatory 
Syndrome in a Rural 
Area of Mozambique 
The incidence, clinical 
characteristics, outcome and 







136 40 8 20 














To determine the 
incidence and timing of TB-IRIS 




Ethiopia 420 49 11 22.4 
Lorrent et al 
(2011) 
PLOS One Incidence and Risk 
Factors of Serious 
Adverse Events during 
Anti-tuberculous 
To determine incidence, causes 
and risk factors for serious 










Journal  Title of paper Primary Objectives Study Design Country Sample 
Size 











Treatment in Rwanda: 
A Prospective Cohort 
Study 
treatment, as well as its impact 
on antituberculous treatment 
outcome. 
Haddow et al 
(2012) 
PLOS One Incidence, Clinical 
Spectrum, Risk Factors 




Syndrome in South 
Africa 
Characterization of IRIS 
incidence, clinical spectrum, risk 
factors and relative contribution 
to mortality of in two urban ART 











STD & AIDS 
Treatment outcomes of 
patients co-infected 
with tuberculosis and 
HIV at Chiang Mai 
University Hospital, 
Thailand 
•To determine treatment 
outcomes among TB/HIV co-
infected patients.  
•to determine the risk factors 
related to death 
and immune reconstitution 
inflammatory syndrome (IRIS) 
Retrospective 
cohort study 
Thailand 171 132 8 6.1 








syndrome in patients 
infected with HIV: 
meningitis a potentially 
life threatening 
Manifestation 
To study the frequency, clinical 





IRIS) in HIV infected patients in 
a TB hospital in North India 
Retrospective 
chart review 
India 103 103 13 12.6 










Initiation in Patients 
With Tuberculosis: 
Findings From the 
SAPiT Trial 
To assess IRIS incidence, 
severity, and outcomes 
relative to the timing of ART 







642 642 80 12.5 




Clinical spectrum, risk 
factors and outcome of 
immune reconstitution 
inflammatory 
Describe the clinical spectrum 









Journal  Title of paper Primary Objectives Study Design Country Sample 
Size 











syndrome in patients 
with tuberculosis-HIV 
co-infection 





Time to Initiate 
Antiretroviral Therapy 
Between 4 Weeks and 
12 Weeks of 
Tuberculosis Treatment 
in HIV-Infected 
Patients: Results From 
the TIME Study 
To determine the 
optimal timing of ART initiation 
to minimize the mortality among 
HIV-infected patients with active 
TB in the setting of 




Thailand 156 156 41 26.3 
Kumarasamy et 
al (2013) 













HAART Initiation in 
South India 
To determine the frequency and 
clinical response 
of developing IRIS among 
HIV/TB-co-infected South 





India 1731 1731 95 5.5 






syndrome after early 
initiation of 
antiretroviral therapy in 
a randomized clinical 
trial 
To analyze cases of paradoxical 
tuberculosis-associated immune 
reconstitution inflammatory 




Cambodia 597 597 155 26 
Van der Plas 
(2013) 






To document causes of clinical 
deterioration of hospitalised 
patients with HIV-associated 
tuberculosis starting 
antiretroviral therapy in order to 
inform healthcare 












Journal  Title of paper Primary Objectives Study Design Country Sample 
Size 











Bonnet et al 
(2013) 






Syndrome and Impact 
on Patient Outcome 
To determine the incidence and 
predictors of TB-IRIS and to 
assess the 
association between the 
occurrence of TB-IRIS and 48-



















To compare ART 
started earlier (within 2 weeks 
after TB treatment initiation) vs. 
later (8-12 weeks after TB 
treatment initiation) in HIV-
infected participants with CD4+ 
cell counts < 250 cells/mm3 







806 806 61 7.6 
•: IRIS specific study objective 
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IRIS associated with TB occurs in 2 distinctive circumstances (72, 73). “Paradoxical” IRIS occurs in 
HIV-infected patients with known TB that are improving while either receiving or having recently 
completed TB treatment but who develop a paradoxical worsening of symptoms, signs, and or 
radiological manifestations of TB, after commencing ART (72, 82). “Unmasking” IRIS occurs when 
HIV infected patients who have no clinical evidence of TB initiate ART and subsequently develop 
clinical manifestations of TB where the inflammatory component is often pronounced (72). In the latter 
group, occult TB infection becomes unmasked following ART induced immune restoration (Figure 5). 
Clinical features of IRIS in TB HIV co-infected patients range from mild clinical presentations, to more 
severe morbidity, or recurrent, new, or deteriorating clinical and radiological manifestations to mortality 
(83). 
 
Figure 5: Paradoxical tuberculosis-associated IRIS, ART-associated tuberculosis, and 
Unmasking tuberculosis-associated IRIS (72) Reproduced with permission from Elsevier (License 
no. 3738170833211) 
 
Other atypical and more severe manifestations include new or progressive serositis, tuberculoma, acute 
renal failure, airway compression, with respiratory failure (70, 72, 73, 84-91). Although IRIS can occur 
in HIV uninfected patients and in the absence of ART, the vast majority of all reported cases occur in 
HIV infected patients after the commencement of ART (70, 72, 73, 84-91). Most reports show that 
paradoxical IRIS occurs within 6 weeks of ART initiation. Risk factors for development of paradoxical 
IRIS include disseminated TB, ART initiation close to tuberculosis treatment initiation, low pre-ART 
CD4 cell count, high baseline viral load and a greater decrease in viral load and larger CD4 cell count 
increase or increase in CD4:CD8 cell ratio from baseline on ART (70-74). IRIS remains a diagnostic 
challenge as it is important to exclude poor adherence to ART or TB treatment, the presence of another 
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opportunistic infection, multidrug resistant TB, or a suspected adverse drug reaction as the underlying 
reason for clinical deterioration, before the diagnosis of TB–IRIS can be made. Treatment of IRIS 
includes the use of corticosteroids and non-steroidal anti-inflammatory agents, both strategies as yet 
poorly defined, and implemented to varying degrees in available published literature (86, 92). Mortality 
associated with TB-IRIS is relatively uncommon overall, however when IRIS affects the CNS, it is 
likely to be life-threatening (67). Concerns about the frequency, severity and clinical outcomes resulting 
from immune reconstitution inflammatory syndrome (IRIS) remained an obstacle to antiretroviral 
therapy (ART) initiation during TB treatment in co-infected patients (Table 5). 
 
“Unmasking” TB occurs when undiagnosed active TB present at ART initiation (72, 73, 85, 91), 
becomes overtly symptomatic after ART initiation. This new, “unmasked” presentation of TB, usually 
occurs in the weeks following initiation of ART, and when accompanied by an exaggerated 
inflammatory clinical presentation, is termed unmasking tuberculosis-associated IRIS. This 
phenomenon, leading to increased numbers of new TB cases diagnosed in newly initiated ART patients, 
may be as a result of restoration of TB-specific immune responses generated by the use of antiretroviral 
therapy (84, 91, 93). The incidence of unmasking TB in programs may vary, dependent on the efficiency 
of screening for clinical and sub-clinical TB in patients preparing for ART initiation. Severity of 
unmasking TB reported in published literature varies. Severe and fatal outcomes of unmasking TB IRIS 
have been reported in a few studies (90, 94), others have shown that this contributes to high mortality 
during the initial months of ART (95), however most published data demonstrate an unremarkable 
clinical presentation (91, 93). The use of ART in HIV-infected patients is a key strategy recommended 
by the World Health Organization (WHO) to prevent TB (96) as it has been shown to reduce the risk 
of developing TB by approximately 70–90% (42, 97-99). While studies from resource-limited settings 
show a decline in TB incidence rates in HIV-infected patients with longer duration on ART (16, 100, 
101), the challenge of the burden of newly diagnosed tuberculosis among rural patients initiating ART 
in a HIV and TB endemic setting has not been fully quantified. 
 
1.5.2 Impact of TB-HIV integration on overlapping drug toxicities 
The TB treatment regimen requires daily intake of either 4 drugs (intensive phase) or 2 drugs 
(continuation phases), whilst HIV treatment requires daily intake of 3 drugs. Each regimen contain 
drugs that may be associated with overlapping and additive side effects and toxicities including gastro-
intestinal intolerance, drug induced liver injury, renal impairment, hypersensitivity reactions, peripheral 
neuropathy, rash and neuro-psychiatric effects (Table 6) (1, 102). 
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Table 6: Shared side effects of antiretroviral and anti-tuberculosis drugs  (1) 
Adverse effects Antiretroviral Drugs Antituberculosis drugs 
Gastrointestinal disturbance and/or pain AZT, ddl, PIs, INSTI RIF, PZA, INH, ethionamide, PAS, clofazamine, linezolid 
Liver injury NNRTIs, PIs, NRTIsa, ABC, Entry inhibitors RIF, INH, PZA, second line drugs including PAS, 
ethionamide, flouroquinolones 
Peripheral neuropathy D4T, ddl INH, terizidone/cycloserine, ethionamide, linezolid 
Neuropsychiatric EFV INH, Terizidone/ cycloserine, ethionamide,  
Renal impairment TDF, Indinivir Aminoglycosides and capreomycin 
Rash NVP, EFV, ABC, Fusion Inhibitors, Entry 
inhibitors 
RIF, INH, PZA, ethambutol, streptomycin second line drugs 
including flouroquinolones, clofazamine 
Blood dyscrasias AZT, 3TC, Fusion Inhibitors Linezolid, rifabutin, INH, rifampicin 
Cardiac conduction abnormalities PIs, Entry inhibitors Bedaquiline, flouroquinolones, clofazamine 
Pancreatitis D4T, ddl, Lop/Rit,  Linezolid 
Lactic acidosis D4T, ddl Linezolid 
3TC 2’, 3’-dideoxy-3’-thiacytidine, ABC abacavir, AZT zidovudine, D4T stavudine, ddl didanosine, EFV efavirenz, INH isoniazid, NRTIs nucleoside 
reverse transcriptase inhibitors, NVP nevirapine, PAS para-aminosalicylic acid, PIs protease inhibitors, PZA pyrazinamide, RIF rifampicin, TDF tenofovir,  
INSTI Integrase strand transfer inhibitor, Fusion Inhibitors eg. Enfuvirtide, Entry inhibitor eg. maraviroc 
aNRTIs   (especially D4T and ddl) can cause steato-hepatitis.  
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Some studies suggest that HIV-infected patients have a higher rate of adverse events whilst other studies 
do not support these findings (103, 104). Few studies assessed the extent of additive side effects and 
toxicities as well as tolerability of co-treating TB and HIV. For instance, one retrospective study 
conducted in South Africa demonstrated that there was no association between co-administration of 
antiretroviral drugs among TB patients and the manifestations of serious and life-threatening adverse 
events (105). Conversely, retrospective studies conducted elsewhere in patients with CD4 cell counts < 
100 cells/mm3, found 66.1% of co-treated patients experienced drug-related adverse events in the first 
2 months (106), with an almost two-fold increase risk of an adverse events (OR: 1.88) with concomitant 
use of ART and TB treatment (44). However, these findings represent data from two small studies 
where two thirds of patients received an ART regimen containing nevirapine (NVP).  
 
Several retrospective studies also found increased risk of adverse events among co-infected vs mono-
infected patients and in those receiving co-treatment vs those receiving ART or TB treatment only. It 
is however important to note that the antiretroviral regimen used in these studies contained stavudine 
and didanosine - drugs no longer in wide usage.  In contrast, regimens containing EFV were found to 
be better tolerated. It is unsurprising that peripheral neuropathy which was reported in nearly half of all 
patients, and hepatotoxicity, were the most common reported toxicities in patients receiving TB-HIV 
co-treatment (107-110). This study showed that the risk of hepatotoxicity increased when ART was 
introduced during the intensive phase of TB treatment (109). In addition, while some studies show that 
concomitant TB treatment in patients on a non-nucleoside reverse transcriptase inhibitors (NNRTI) 
based ART regimen has been associated with an increased risk of drug induced liver injury (DILI) (109, 
111, 112) other studies show otherwise (113). These studies cite elevated baseline transaminases and 
hepatitis B antigenaemia as likely risk factors (114-123) for increased risk of drug induced liver injury 
(DILI). Hoffman et al, showed an 8.5-fold increased risk of hepatotoxicity with ART initiation in TB 
therapy (109).  
 
One cohort study demonstrated low morbidity and mortality in HIV-infected patients with DILI (109), 
however in another South African study, approximately one third of all HIV infected patients admitted 
to hospital with DILI, died. This occurred either during TB treatment only, ART only, or in concurrent 
therapy (124), with sepsis and liver failure cited as reasons for death. Renal dysfunction reported in 
isolated case reports resulting from overlapping toxicity with use of tenofovir, rifampicin and 
aminoglycosides, has however not been confirmed in cohort studies (88). 
 
In a meta-analysis (125), of six randomized control trials, 50.7 % of patients receiving early ART 
initiation vs. 51.5 % of patients receiving delayed ART initiation during TB treatment, experienced 
grade 3–4 drug-related adverse events, pooled IRR = 0.99,  noting high quality of evidence and no 
observed limitations. Extensive literature review shows a general paucity of prospectively collected 
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data within RCTs describing the frequency of ART drug changes from treatment-limiting toxicity or 
virological failure in TB-HIV co-infected patients.  
 
1.5.3 Cost effectiveness of TB HIV treatment Integration 
In resource constrained settings, strategic prioritization of efforts to integrate services for co-occurring 
endemic diseases are essential. The management of HIV associated TB presents an opportunity to assess 
the cost-effectiveness of an integrated approach to care in comparison to the treatment of HIV and TB 
at separate care sites. The costs of screening for TB range from large, e.g. GeneXpert which costs 
between $15-32; to moderate e.g., chest x-ray which costs about $9-17 and small e.g. TB symptom 
screen via history (126) (127).  The costs of TB treatment also range widely with a 6-month course of 
first-line therapy costing approximately $6, second-line MDR-TB therapy costing $120, and treatment 
for XDR-TB costing $180 (126). The additional costs of providing TB care include infrastructure for 
provision of services, personnel, and training (127). Costs of integrated HIV/TB care have been less 
well-described, with the actual differences in overall costs of integrated screening and treatment for TB 
with HIV needing further evaluation.  
 
Published studies have examined cost-effectiveness of various TB diagnosis strategies of TB in HIV-
infected patients, and of HIV in TB patients (128-133). One study from India suggested that integrating 
HIV testing into TB treatment clinics was “very cost-effective,” with an incremental cost-effectiveness 
ratio of $730/year of life saved (YLS), well below the Indian per capita annual GDP of $1,500 (134). 
Modelling data from South Africa comparing specific TB screening methods in HIV-infected patients 
(14, 129) found that Xpert MTB/RIF tests used in routine TB screening among HIV-infected patients 
were cost-effective when compared to symptom screening and sputum smear or sputum culture. 
Nevertheless to our knowledge, no studies have assessed the comparative effectiveness and cost of fully 
integrated HIV/TB programs. 
 
Cost and cost-effectiveness of ART has been extensively researched in SSA, including provision of 
ART, treatment monitoring strategies, and regimen choices (135-142). However, no studies have 
studied comparative costs or cost-effectiveness of different timing of ART initiation in TB therapy for 








Data for this dissertation is drawn from two CAPRISA studies: The CAPRISA 003 Starting 
Antiretrovirals in Three Points in Tuberculosis Therapy Trial (SAPIT); and the CAPRISA AIDS 
Treatment (CAT) Programme.  
 
2.1. The SAPiT Trial 
Setting: The SAPIT trial, a three-arm, prospective, randomized, open-label clinical trial, was conducted 
at the CAPRISA eThekwini Clinical Research Site (ECRS), from June 28, 2005, to July 11, 2010. 
Patients recruited for participation into the SAPiT trial were drawn from the Prince Cyril Zulu 
Communicable Disease Centre (PCZCDC), a Primary Health Care Clinic dedicated to treating 
ambulatory patients with TB and sexually transmitted infections which is located alongside the 
CAPRISA ECRS. This municipal facility is conveniently located in central Durban in the transport hub 
for public commuters by rail, bus or minibus taxis. It is across from the central train station with the 
commuter taxi ranks on the one side and Durban’s central fresh produce farmer’s market with its linked 
main bus terminus on the other side. The PCZCDC is one of the largest out-patient TB facilities in 
South Africa with a sophisticated computerized patient record system.  The PCZCDC provides care to 
patients from North and South Central Durban, a city with a population of about 3 million inhabitants, 
with over 10,000 cases of TB annually. PCZCDC notifies approximately 3,500 new TB cases per 
annum. Patients who present to the facility for TB screening and treatment are mostly unemployed 
(53%), with a median age of 33 years (range: 5-72), 39% are women and 69% are HIV co-infected 
(personal communication Dr Surie Chinappa, Medical Manager, PCZCDC). 
 
Background therapy: Management of tuberculosis followed the National Tuberculosis programme 
guidelines which recommended that all first episode tuberculosis cases be treated with a 2-month 
intensive phase of a combination-drug regimen of rifampicin, isoniazid, ethambutol, and pyrazinamide, 
with doses based on pre-treatment weight. Thereafter, patients receive the 4-month continuation phase 
regimen consisting of isoniazid and rifampicin. Patients with retreatment tuberculosis receive a 3-month 
intensive phase regimen, which also includes streptomycin for the first 2 months, followed by a 5-month 
continuation phase regimen consisting of isoniazid and rifampicin. All patients were also routinely 
provided with cotrimoxazole prophylaxis. 
 
SAPiT Trial Methods: Adult patients at least 18 years or older with confirmed HIV infection (based 
on two rapid HIV tests) with sputum smear positive tuberculosis diagnosed using auramine and Ziehl–
Neelsen staining methods, and a screening CD4 count < 500 cells/mm3 were recruited for possible trial 
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participation. Patient eligibility criteria for study participation included independent microbiologic 
confirmation of positive tuberculosis status and absence of clinical contraindications to initiation of 
standard tuberculosis treatment or antiretroviral therapy. All female patients enrolled needed to agree 
to use dual contraception while taking efavirenz.  
 
Randomisation: Patients provided written informed consent, and were thereafter randomly assigned in 
a 1:1:1 ratio, with the use of sealed envelopes, to one of three study arms in permuted blocks of six or 
nine with no stratification, as per a random allocation sequence generated by the study statistician. 
Patients were randomly assigned to initiate ART within 4 weeks of tuberculosis treatment initiation 
(early integrated treatment arm), within 4 weeks after intensive phase of tuberculosis treatment 
completion (late integrated treatment arm), or within 4 weeks after tuberculosis therapy completion 
(sequential treatment arm) (Figure 6). The standard first-line ART regimen consisting of once daily 
didanosine (250 mg for patients with a body weight of <60 kg and 400 mg for a body weight ≥60 kg), 
lamivudine (300 mg), and efavirenz (600 mg). Placebos were not used in this trial. All patients received 
adherence counselling, and adherence to the antiretroviral regimen was assessed via monthly pill 
counts. In addition, patients could be started on ART on clinical grounds, based on clinician’s discretion 
regardless of arm assignment.  
 
 
Figure 6: SAPiT Trial Schema (77) 
 
Follow-up: Follow-up visits were scheduled monthly for 24 months, for monitoring of patient safety 
and clinical status. All clinical and laboratory related adverse events were graded with the use of the 
National Institute of Allergy and Infectious Diseases Division of AIDS Table for Grading the Severity 
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of Adult and Paediatric Adverse Events, version 1.0, (December 28, 2004). CD4+ cell counts and HIV 
RNA measurements were performed at screening, randomization, and 6 monthly thereafter. Chest 
radiographs and sputum microbiologic examination was performed at screening, at the end of the 
intensive phase of TB therapy, 1 month before the end of TB therapy, and on clinical indication. 
 
The SAPiT trial sample size calculated as 649 patients, was based on the primary mortality outcome of 
the study. Statistical analyses were done using SAS (version 9.2; SAS Institute Inc., Cary, NC, USA). 
All statistical tests were two sided. All reported P values are 2-sided. TB incidence was calculated as 
number of new TB cases after ART initiation per 100 person-years (py) of follow-up. The primary 
outcome was analysed with the use of Kaplan–Meier curves and the log-rank test. Poisson 
approximations were used to calculate confidence intervals (CIs) and incidence rate ratios (IRRs). Cox 
proportional- hazards regression was used to adjust for confounding variables. Fisher’s exact test or 
Fisher-Freeman-Halton test was used for analysis of categorical data, and unpaired t-tests or Wilcoxon 
two-sample, one way ANOVA, or the Kruskal-Wallis tests were used for the analysis of continuous 
data.  
 
The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, 
reference number: E107/05 and the Medicines Control Council of South Africa reference number.  
N2/19/8/2 (2137).  
 
2.2. The CAPRISA AIDS Treatment (CAT) Programme 
A prospective cohort study was conducted among 969 adult HIV-positive patients, a subset of patients 
from the rural Vulindlela CAT programme that initiated ART between 2007 and 2010. Vulindlela, 
located in the province of KwaZulu-Natal, is a rural village of about 400 000 predominantly Zulu 
speaking people. Free ART provided through PEPFAR supported HIV services, was offered as per 
current South African National HIV treatment guidelines (144). Ambulant HIV infected patients, 
predominantly ART naïve patients were initiated on ART if eligible as per guideline criteria. All 
patients were screened for TB by health care workers using a standardized TB clinical symptom 
checklist that screened patients for symptoms of drenching night sweats, fever, prolonged cough, and 
weight loss at every clinical visit. All TB suspects were referred for TB smear testing to the 
neighbouring government Primary Health Care Clinic. All patients that were tuberculosis sputum 
smear-positive were initiated onto anti-TB therapy upon receipt of microbiologic results while smear-
negative patients routinely received sputum culture testing and a trial of antibiotic therapy. Diagnosis 
and treatment of TB followed South African National TB Control Program guidelines (30). Smear- and 
culture-negative TB suspects, showing poor response to antibiotic therapy, and those patients in whom 
extra-pulmonary TB was suspected, were referred to the nearest local hospital for further investigation 
and management. Patient follow-up data was censored at twenty four months for this analysis. 
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This study was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, 
ref no: E248/05. 
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THE RISKS AND BENEFITS OF HIV AND TB TREATMENT INTEGRATION 
 
Chapters 3, 4 and 5 highlight important contributions to understanding the impact of timing of ART 
initiation in TB treatment on mortality. These studies conclude that early ART initiation in TB patients 
with low CD4 cell counts significantly improved AIDS-free survival. This holds true for all co-infected 
patients except those with TB meningitis. This was, however, accompanied by a significant increase in 
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IMMUNE RECONSTITUTION DISEASE – A MAJOR IMPEDIMENT TO 
TB - HIV INTEGRATION 
 
Chapter 6 presents secondary analysis of SAPiT trial data, addressing important concerns about 
incidence, severity, and outcomes of IRIS relative to timing of ART initiation in TB-HIV co-infected 
patients. This study highlighted significantly higher IRIS rates, more severe cases of IRIS, longer time 
to resolution, and more frequent hospitalization among patients receiving early integrated ART in TB 
therapy. Chapter 7 addresses the other distinct form of ART induced TB associated IRIS. This paper 
highlights the high rates of unmasking TB in a rural ART programme, irrespective of baseline CD4 
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DRUG SWITCHING FROM ADDITIVE TOXICITY IN TB-HIV CO-TREATMENT - 
ARE THE CONCERNS LEGITIMATE? 
 
Chapter 8 presents secondary analysis of SAPiT trial data and assesses the impact of TB HIV co-
treatment on additive toxicity and virologic failure. There were low rates of drug switching due to 
toxicity in all study arms, with virologic failure commoner in those with CD4 counts < 50 cells/mm3. 
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CHAPTER 8 
CHANGES TO ANTIRETROVIRAL DRUG REGIMENS DURING INTEGRATED 
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COSTS AND COST EFFECTIVENESS OF CO-TREATMENT 
 
Chapter 9 presents secondary analysis of SAPiT trial data assessing costs and cost-effectiveness of ART 
timing relative to TB treatment. This study demonstrated that ART initiation after the intensive phase 
of TB therapy was most cost-effective in patients with CD4 counts > 50 cells/mm3, with important 
implications for policy makers and funders. 
Chapter 10 is a review paper that explores expanding and adapting the lessons learned from the 
integration of TB and HIV to other non-communicable diseases (NCD) and describes the data needed 
for cost-effectiveness analyses. Cervical dysplasia and depression are used as case studies on how 
integration of NCDs with HIV care could be cost-effective. 
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11.1.1 Impact of ART timing in TB therapy on mortality 
Despite the availability of safe and effective treatment for each of TB and HIV individually, co-treating 
these diseases presents several clinical challenges. The purpose of this doctoral research was to evaluate 
the clinical and programmatic challenges in integrating TB and HIV care in order to guide policy and 
programmatic implementation.  
 
The Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPIT) trial showed a 56% 
reduction in mortality when ART was integrated with TB treatment, compared to when ART initiation 
was deferred to after TB treatment completion (57, 58). This study further described unexpectedly high 
mortality long after cessation of TB therapy in co-infected patients not initiated on ART. Findings from 
this study was rapidly incorporated into local and global policy guidelines, creating an impetus for the 
integration of TB and HIV care.  
 
Further analysis of study data showed no difference in incidence rate of AIDS or death when comparing 
ART initiation among patients randomised to the early arm versus late arm (58). However, among 
patients with CD4 cell counts <50 cell/mm3, the incidence rate of AIDS or death was significantly lower 
in those receiving early vs delayed ART initiation in TB therapy. Similar findings were published from 
two other randomised clinical trials (60, 62), the AIDS Clinical Trials Group (ACTG) Study 5221 
(STRIDE) (62), and the Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA) 
study (60).  
 
A model, which was created in Rwanda, to predict the impact of different ART initiation strategies in 
TB patients on 2-year survival rates, concurs with findings of reduced mortality and improved retention 
in care among individuals with low CD4 cell counts that initiate ART early (46). A recently published 
systematic review and meta-analysis of eight randomised controlled clinical trials (n = 4568) (1, 145), 
conducted in the United States, Africa, Asia, that investigated optimal timing of ART in TB patients, 
concluded that early ART reduced mortality compared with delayed ART (relative risk [RR], 0.81). In 
patients with baseline CD4 cell count <50 cells/mm3, early ART decreased mortality compared with 
delayed ART (RR, 0.71) (145). The mortality benefit from early ART was however not found among 
those with CD4 cell count > 50 cells/mm3, (RR, 1.05) (Figure 7) (145). 
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Figure 7: All-cause mortality comparing early vs. delayed initiation of ART across RCT’s ART 
across randomized control trials of TB-HIV treatment (145). Reprinted with the permission of 
American College of Physicians, Inc. (Licence number 3750761222329).  
 
Data from these studies provide clear evidence on the optimal timing of ART initiation in patients with 
HIV associated pulmonary TB. They demonstrate that TB-HIV co-infected patients with advanced 
immunosuppression defined as CD4 cell count <50 cells/mm3, benefit from initiating ART within 2 
weeks of TB treatment initiation (57, 58, 60, 62). Among patients with higher CD4 cell counts defined 
as CD4 cell count >50 cells/mm3, however, the incidence of AIDS and/or death were similar irrespective 
of initiation of ART early or later during TB treatment. An evaluation of other co-morbid clinical 
conditions may be warranted when determining the optimal timing of ART initiation in TB-HIV co-
infected patients with higher CD4 cell counts. 
 
11.1.2 TB-HIV Integration and Immune Reconstitution Inflammatory Syndrome 
11.1.2.1 Paradoxical TB IRIS 
TB Immune reconstitution inflammatory syndrome (IRIS), a paradoxical clinical deterioration in 
patients on effective TB treatment, remains the major hurdle to antiretroviral therapy (ART) initiation 
during tuberculosis treatment (70, 74, 86). Published reports of high incidence rates of IRIS from 
diverse settings has been one of the most important and often cited reason for delays in initiation of 
ART in patients receiving TB treatment (70, 73, 74, 84, 86, 90, 91, 146). In a review of 40 retrospective, 
cohort observational and randomised studies, pooled incidence of paradoxical TB-IRIS was 18%, 
(range from 4% to above 50%) (74). IRIS risk varied by study design, geographic location and whether 
inpatients or outpatients were studied (70, 73, 74, 84, 86, 90, 91, 146). Furthermore, higher risk of 
paradoxical TB IRIS was associated with ART initiation proximal to tuberculosis treatment initiation, 
and among patients with baseline CD4 cell counts <50 cells/mm3 (58, 60, 62, 85, 87, 89, 147, 148). 
Data from RCTs including the SAPIT, CAMELIA, and STRIDE studies also provide some insights 
into the frequency of IRIS relative to ART timing (77, 149, 150). 
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In the SAPiT trial, we found IRIS incidence rates of 20.1 and 7.7 cases per 100 person-years in the early 
and late groups (incidence-rate ratio (IRR): 2.62; 95% CI, 1.48 to 4.82; p<0.001), respectively.  
Furthermore, patients with CD4 cell count <50 cells/mm3 had approximately five times higher incidence 
rates of IRIS in the earlier compared to later-ART group (p = 0.01). In addition, there was 2-fold higher 
paradoxical TB IRIS rates in patients with baseline CD4 cell count ≥ 50 cells/mm3 randomised to earlier 
ART, compared patients randomised to later ART (77). 
 
The CAMELIA trial reported  36% (110/308) versus 16% (45/289) IRIS events in the early and late-
ART groups, (2.61; 95% CI: 1.84–3.70 ; p<0.001) (62, 149); while the STRIDE study (60, 150) found 
a two-fold higher IRIS rates in the immediate compared to late ART groups,(10.4% vs 4.7% p=0.002), 
respectively. Like in the SAPIT trial, the STRIDE trial showed a higher risk of TB-IRIS with early ART 
in patients with baseline CD4 cell count <50 cells/mm3 (18.8% early vs 4.3% later) (60, 150). However, 
there was no difference in IRIS risk with earlier ART timing in patients with CD4 cell count ≥ 50 
cells/mm3, (5.7% early vs 5.0% later) (60, 150). Cumulative TB-IRIS incidence rates reported in the 
Thai TIME trial, was 32.9 in the 4 week and 19.4% in the 12 week arms (RR: 2.03) (63). All four RCTs 
investigating ART timing in TB therapy confirm previous published findings from observational 
studies: earlier ART increases TB-IRIS risk; provides the evidence that quantifies IRIS risk (two- to 
threefold higher risk with ART initiation at 2 weeks vs. 8–12 weeks of TB therapy) and gives evidence 
for heightened risk in patients with CD4 cell counts <50 cells/mm3 (58, 60, 62, 63). The systematic 
review and meta-analysis published by Uthman et al, also showed higher incidence of TB-IRIS 
associated with early ART compared to delayed ART (RR, 2.31) (145). 
 
The finding of low IRIS-associated mortality in the SAPiT trial, was not unique. Despite heterogeneity 
in baseline characteristics and setting, mortality from IRIS was low overall in all three RCT’s (58, 60, 
62). IRIS-associated deaths reported in the CAMELIA (n=6) (60, 149), TIME (n=1) (63) and SAPiT 
(n=2) (77) studies occurred in patients randomised to earlier-ART initiation. Although the STRIDE 
study (62, 150), reported no IRIS associated deaths, the Torok et al TB Meningitis trial showed 
extremely high mortality rates from intracranial IRIS reported in both study arms (67). Overall the low 
rates of IRIS-associated mortality demonstrated in all these different studies denotes that scale-up of 
TB-HIV integration can be done without fear of worsening IRIS associated morbidity and mortality or 
of increasing resources needed for management of paradoxical TB IRIS. 
 
The overall incidence rates of paradoxical TB IRIS in published RCT’s were not as high as previous 
reports (60, 62, 63, 67, 77, 149, 150). As patients with advanced immunosuppression are at highest risk 
of developing paradoxical TB IRIS, the balance of improved survival when initiating ART earlier 
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during TB treatment outweighs the increased IRIS risk. A diagnostic marker suitable for routine clinical 
and laboratory settings that will enable efficient IRIS diagnosis and further management, is needed. 
 
11.1.2.2 Unmasking TB 
We found alarmingly high TB incidence rates (11.5/100 py) among HIV infected patients in the first 3 
months post ART initiation, while incident TB identified during 4-24 months of follow-up post ART 
initiation, was not as high (3.2/100 py), p <0.001. TB incidence rates remained consistently high 
irrespective of a baseline CD4 cell count of < 50 or > 200 cells/mm3 (57, 58, 77). In another published 
report from South Africa, unmasking TB accounted for more than one third of all TB cases that 
presented during the first 4 months of ART (93). The relative contribution of unmasking TB IRIS to 
the high rates of incident TB is largely unknown due to diagnostic complexities. Unlike paradoxical 
tuberculosis-associated IRIS, the understanding of unmasking TB IRIS is less clear. High rates of 
tuberculosis are diagnosed in ART programmes in resource-limited settings, due to varied reasons.  TB 
may present as a result of ongoing immune deficiency, due to previously missed diagnosis, flare-up of 
active subclinical disease due to restoration of ART-induced TB immune responses.  
 
The data we present demonstrates an inverse relationship between TB incidence and time on ART, 
demonstrating highest rates of TB due to “unmasked” infection in the first three months post ART 
initiation, highlighting the need for close monitoring for TB in this period. Additionally, this data is in 
keeping with published reports that demonstrate continued high incidence rates of new TB infections 
even at 24 months post ART initiation. These reports show that despite the decline of TB incidence 
with time on ART, ART-accessing patients remain at heightened risk for TB, at rates far higher than in 
the general HIV uninfected population (151).  
 
Other publications report a far more considerable time dependant decrease in TB incidence among 
patients on ART (152-161), reporting highest TB incidence rates during the first 3 months of ART (96), 
with a reduction in all forms of TB from 5.77/100 to 2.23/100 py (162) during the first year of follow-
up. Differences in background risk of TB infection, is a likely contributor to varying TB incidence rates 
among patients on ART in other settings. Published meta-analysis data from a developed country show 
that among patients accessing ART, TB incidence rates were estimated at 3 per 1000 py; which is 
approximately 10 fold lower than the TB incidence rates we found (96). Moreover, recently published 
TB incidence rates estimates TB incidence rates of 7.43 per 1,000 person years over a 10-year period 
among patients receiving HIV Treatment in Nigeria (163). Findings similar to ours, emerged from an 
urban informal settlement in Cape Town, which has a background TB notification rate of >1000/100 
000 population and HIV sero-prevalence of 28%. Here, TB incidence reduced from 22.1 after 
approximately three years of ART, to 4.5/100 py (164, 165). A meta-analysis of 9 studies evaluating 
ART associated TB risk reduction found that most studies (n = 6), showed ART-associated risk 
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reduction of > 70% (IQR: 54% to 92%), irrespective of setting or background TB burden (42, 99, 166-
170). TB rates during ART appear to be dependent on the duration that patients spend at low CD4 cell 
counts. This is further complicated by the high risk for nosocomial TB infection due to care in 
congregate settings with poor infection TB control practices, which is typical of most ART programmes 
in sub-Saharan Africa (171).   
 
11.1.3 TB-HIV Integration and Impact on Additive Drug Toxicity 
Our study shows that the risk of treatment limiting additive drug toxicity was low with TB-HIV co-
treatment. Overall, we found low rates of drug switching from toxicity in all three arms, and no 
significant difference in the incidence rate of drug switches secondary to toxicity between the treatment 
arms (57, 58). Concerns that treating TB and HIV simultaneously will worsen rates of additive toxicity 
and undermine TB and HIV treatment outcomes was also assessed in the CAMELIA (60), and STRIDE 
studies (62). The trials all demonstrated similar rates of drug toxicity irrespective of treatment group 
assignment. 
 
The most common drug toxicities warranting drug change in our study were neuropsychiatric side-
effects (n=4), hyperlactatemia and elevated transaminase levels (n= 3) and, peripheral neuropathy 
(n=2). These occurred mainly in the first six months (11/15 events) post ART initiation, and was most 
likely due to our choice of first line ART regimen (172). It is important to note that these findings may 
not be generalizable to a sicker population, or to those taking a different background ART or TB 
regimen, as this study was conducted in ambulant, patients with pulmonary TB. 
 
11.1.4 Costs and Cost-Effectiveness of ART timing in TB treatment 
GDP per capita is the benchmark used to select cost-effectiveness of interventions in countries such as 
South Africa, where a cost-effectiveness threshold remains to be established. An intervention is 
considered cost-effective if it costs between one and three times annual GDP per capita. Until now, 
there was a lack of objective evidence as to whether integration of services will contribute to increased 
or decreased costs to the healthcare provider. On one hand, integration of HIV and TB services could 
potentially save money through shared use of resources, which includes: monitoring and evaluation 
systems, medicine supply chain management, laboratory equipment, shared human resources and 
infrastructure (48, 173, 174). However, TB-HIV co-treatment could also increase costs, as ART is 
provided to larger numbers of patients and more resources may be required, such as clinical 
infrastructure, systems to manage complications of co-treatment and additional staff and staff training 
(48). 
 
Timing of ART initiation during TB treatment has repercussions for cost and quality of health service 
delivery.  In patients with CD4 cell counts <50 cells/mm3, the mortality benefit of starting ART early 
139 
during TB treatment is well-defined (58, 62) and far outweighs any implications of higher cost.  
However, in patients with CD4 cell counts >50 cells/mm3, the best time to initiate ART during TB 
treatment is less well-defined as survival was similar among patients initiating ART within one month 
or after 2 months of TB treatment start. In the context of this unclear survival benefit with earlier ART 
initiation in TB therapy, questions of cost-effectiveness, and affordability became important 
considerations for health funders and planners. Increased costs of care with early integrated ART are 
linked to more frequent hospitalisation, more numerous diagnostic investigations for IRIS and drug 
toxicity, compared to late integrated care.   
 
In assessing the costs and cost-effectiveness of initiating ART at three points in TB treatment in patients 
with CD4 cell counts >50cells/mm3, late initiation of ART during TB treatment (Arm-2) was shown to 
be the most cost-effective strategy for patients with CD4 cell counts >50cells/mm3 (175). Mortality and 
costs was similar in Arm-1 and Arm-2.  Arm-3, while having the highest mortality, also showed the 
lowest costs. The 2009 annual GDP per capita in South Africa was $5758. We found the cost per death 
averted in moving from sequential to late integrated treatment was $4199 per annum, an amount below 
the 2009 prices, consequently supporting ART integration at the end of the intensive phase of TB 
treatment, for South Africa.  Arm-1, while marginally more expensive, has slightly higher mortality 
than Arm-2, indicating that Arm-2 is the better choice both in terms of both mortality outcomes and 
cost (175).  
 
Laboratory testing, hospitalization, outpatient care and drugs make up the four key cost components 
that need to be considered when treating TB and HIV co-infected patients. Laboratory investigations 
accounted for the biggest contributor of costs in all three arms, (10.7% in Arm-3, 43.0% in Arm-2 and 
35.5% in Arm-1).  While spending on laboratory tests was lower in Arm-1 than in Arm-2 (p=0.005), 
these costs will likely be lower in routine settings adopting a managed care approach and less frequent 
testing.  The cost of ART contributed sizeably to total variable costs in Arm-1 (32.4%) and Arm-2 
(28.7%). It is worth noting however, that costs of routine and safety laboratory investigations and costs 
of drugs used to treat complications are likely to shrink as duration on ART increases, a reduction in 
ART prices due largely to use of generic fixed drug combinations (175).  
 
Hospitalization, while accounting for a significant amount of Arm-3 costs, was more variable than other 
costs.  Arm-3 had higher hospitalization costs, due to there being more patients hospitalized and longer 
hospital stays among the sick patients in this group. With the wide-scale adoption of the late integrated 
strategy for co-infected patients in endemic settings, it is worth noting that health planners should expect 
to spend approximately $1086 per patient hospitalized.  
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Patient survival and costs in Arm-1 and Arm-2 were similar (175).  Patients in the late integrated 
treatment arm did however experience fewest serious adverse events, IRIS events and hospitalizations, 
which are all associated with significant costs especially in the provision of TB and HIV services.  
Notwithstanding the small differences in cost between Arms-1 and-2, given the magnitude of the TB-
HIV co-infection epidemic in sub-Saharan Africa, the choice of late initiation of ART in TB could lead 
to substantive savings.  
 
The costs in this study were higher when compared to published data from programs offering HIV care 
and treatment services only (141, 176). The higher costs in this analysis can be attributed to the clinical 
trial context which typically has more frequent monthly visits, frequent and intensive laboratory 
monitoring, higher patient to staff ratio and longer staff time allocated per patient compared to routine 
care settings. Furthermore, the inclusion of hospitalization costs, and the relatively high labour costs in 
South Africa, also account for higher costs in this analysis (177). Despite these factors, the relative 
differences in the costs of implementing these three treatment strategies is likely to be similar in other 
settings.  Interestingly, the Clinton Health Access Initiative (CHAI) published findings that compared 
the total cost of treating HIV in South African health facilities with four other African countries, and 
found that costs in South Africa was $682 per annum, compared to an average of $200 per annum the 
other countries (139). Hospital and TB-related costs were not presented in this study’s analyses. Data 
reporting costs of providing HIV-treatment within PEPFAR-supported programs in other low and 
middle income countries also show average costs of $880 per annum. Costing analysis conducted at a 
single ART clinic in Haiti suggested that TB-HIV integration was a strategy to safeguard clinician time, 
concluding that integration involved small cost and time increases when compared to treating HIV alone 
(178, 179). These studies while estimating lower per annum costs in HIV treatment provision, do not 
account for hospital costs, or TB-related costs which were included in this analysis (139, 141). 
 
In summary, it is estimated that South Africa could save more than $7 million per annum by 
implementing the strategy of late integration of ART rather than the early integration strategy in patients 
with CD4 cell counts >50 cells/mm3. To derive this we assume coverage of 70% of the projected burden 
of HIV-TB co-infected patients, and that all patients had drug susceptible pulmonary TB, if the cost 
difference between Arm-1 and Arm-2 is estimated at $3.11 per month (175).  
 
11.2 Limitations 
The SAPIT trial included only ambulant patients with sputum smear positive TB, therefore the results 
presented here may not be directly generalizable to all forms and severity levels of TB, e.g. smear 
negative TB, extra-pulmonary TB etc. Furthermore, while there were no significant differences in 
patient retention across the  study arms, it may be likely that as a result of more patients being retained 
in the early integrated treatment arm, endpoint ascertainment of mortality, IRIS, and drug toxicity was 
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greater here than in the other 2 arms. Although CD4 cell count was a strong predictor of mortality and 
of IRIS risk, it is important to note that CD4 cell count testing is not always available in many settings. 
Furthermore the use of CD4 count to determine eligibility for ART in TB HIV co-infected patients has 
recently been removed from WHO guidelines. Therefore, decisions regarding ART timing in patients 
need to be tempered by clinical judgment of disease severity together with an assessment of existing 
capacity to diagnose and manage these clinical complexities. The use of retrospectively collected data 
within the CAT program, limited access to diagnostic microbiologic and radiologic services 
compounded by missing data elements of routinely collected data, may have led to an underestimation 




The overall aim of this study was to assess the impact of ART initiation in TB-HIV co-infected 
patients with respect to mortality; unmasking TB; TB associated immune reconstitution inflammatory 
syndrome, drug tolerability and additive toxicity, and costs and cost effectiveness of co-treatment. 
Notwithstanding the limitations of these studies, the following outcomes and conclusions can be 
drawn from this series of studies: 
 
a. Mortality: Initiation of ART in TB treatment in TB-HIV co-infected patients resulted in a 
56% survival benefit. This benefit was more profound in patients with a CD4 counts < 50 
cells/mm3 
 
b. Unmasking TB following ART initiation: High rates of newly diagnosed TB was found in 
HIV infected patients in the first three months post ART initiation, irrespective of a baseline 
CD4 cell count of < 50 or > 200 cells/mm3 
 
c. IRIS incidence, severity and outcomes: Initiation of ART early during TB treatment resulted 
in significantly higher IRIS rates, longer time to resolution, and more severe cases of IRIS 
requiring hospitalization. 
 
d. Costs and cost effectiveness of  integration: The most cost-effective strategy for patients with 
CD4 cell counts >50cells/mm3  is the late initiation of ART during TB treatment  
 
e. Additive drug toxicity and tolerability with TB-HIV integration: Additive drug toxicity from 
co-administration of TB and HIV drugs is of limited concern in TB-HIV co-treatment 
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Tuberculosis is the most common cause of death in HIV infected individuals. The evidence 
demonstrates that initiation of ART during TB treatment improves survival in TB HIV co-infected 
patients. While TB-HIV co-infected patients with severe immunosuppression have a five-fold risk of 
IRIS with early ART initiation in TB therapy, the clear survival benefit out-weighs this risk. In stable 
ambulant patients with CD4 cell counts ≥ 50 cells/mm3,   deferring ART to 8 weeks after tuberculosis 
treatment initiation may be a recommended strategy since with this approach IRIS incidence is lower, 
IRIS events are less severe, and the risk of AIDS or mortality is not increased. The survival benefit from 
early initiation of ART in TB-HIV co-infected patients outweighed the concerns of overlapping drug 
toxicities. We found relatively low rates of drug switches and complete regimen changes from virologic 
failure among co-treated patients. Manageable toxicities occurred early, affecting small numbers of trial 
participants. The burden of the dual epidemics of TB and HIV is most severe in sub-Saharan Africa, a 
region with constrained budgets dedicated for health, infrastructure, human resources, and poor 
practices in TB infection control. The programmatic burden of sustaining the costs associated with 
integrated care in this environment has been addressed through the demonstration that late integrated 
treatment has substantial cost reduction over early integrated therapy in stable patients with CD4 counts 
> 50 cells/mm3.  
 
Findings from the work presented here has been incorporated into local and international guidelines and 
has been used to inform TB-HIV integration policy aimed at improved patient outcomes and public 
health benefit, especially in TB and HIV endemic settings.  However, it is important to acknowledge 
that several operational and implementation challenges need to be overcome in order to translate the 
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